Analysts expect Cue Biopharma, Inc. to report revenue of 1.47 M for Q3 26, against a range of 1.35 M to 1.59 M. The most recent reported quarter, Q2 26, came in at 7.88 M, a 148.4% beat against the 3.17 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 3.34 M | 1.58 M | 421,000.00 | 2.95 M | 2.15 M | 21.94 M | 5.69 M | 7.88 M | - | - |
| High Estimate | 1.68 M | 1.94 M | 1.31 M | 2.22 M | 2.40 M | 1.08 M | 2.91 M | 3.37 M | 1.59 M | 1.73 M |
| Low Estimate | 1.49 M | 1.63 M | 1.10 M | 2.02 M | 1.99 M | 990,813.83 | 2.44 M | 2.98 M | 1.35 M | 1.45 M |
| Consensus Estimate | 1.58 M | 1.79 M | 1.21 M | 2.12 M | 2.20 M | 1.04 M | 2.67 M | 3.17 M | 1.47 M | 1.59 M |
Analysts expect Cue Biopharma, Inc. to report earnings per share of -1.41 for Q3 26, against a range of -1.52 to -1.30. The most recent reported quarter, Q2 26, came in at -24.14 , in line with the -1.65 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -5.10 | -3.90 | -5.10 | -2.70 | -2.10 | 0.30 | -1.08 | -24.14 | - | - |
| High Estimate | -4.88 | -2.27 | -4.20 | -3.64 | -2.78 | -2.61 | -2.82 | -1.49 | -1.30 | -1.15 |
| Low Estimate | -5.64 | -2.61 | -4.58 | -4.44 | -2.98 | -3.17 | -3.32 | -1.81 | -1.52 | -1.23 |
| Consensus Estimate | -5.26 | -2.44 | -4.39 | -4.04 | -2.88 | -2.89 | -3.07 | -1.65 | -1.41 | -1.19 |